The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Hitting back at HCC: future landscape of treatment
The future landscape of hepatocellular carcinoma (HCC) treatment is discussed by Jean Frédéric Blanc of the Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. Dr Frédéric Blanc speaks from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, providing an overview of the current TKIs and monoclonal antibodies used in the first-line and second-line treatment of HCC, while discussing the prospective future for HCC treatment. Dr Frédéric Blanc expects to see clinical trials that further investigate the role of checkpoint inhibitors and combination therapies in HCC.
